Evoke Pharma, Inc.
EVOK
$3.30
$0.216.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.31M | 2.65M | 2.55M | 1.74M | 1.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.31M | 2.65M | 2.55M | 1.74M | 1.68M |
| Cost of Revenue | 118.50K | 104.00K | 41.50K | 92.50K | 59.00K |
| Gross Profit | 3.19M | 2.55M | 2.51M | 1.64M | 1.62M |
| SG&A Expenses | 4.38M | 3.82M | 3.73M | 3.14M | 3.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.50M | 3.94M | 3.77M | 3.24M | 3.56M |
| Operating Income | -1.19M | -1.29M | -1.22M | -1.50M | -1.89M |
| Income Before Tax | -1.19M | -1.31M | -1.27M | -1.58M | -1.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.19M | -1.31M | -1.27M | -1.58M | -1.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.19M | -1.31M | -1.27M | -1.58M | -1.99M |
| EBIT | -1.19M | -1.29M | -1.22M | -1.50M | -1.89M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.34 | -0.94 | -0.91 | -2.09 | -7.13 |
| Normalized Basic EPS | -0.21 | -0.59 | -0.57 | -1.30 | -4.46 |
| EPS Diluted | -0.34 | -0.94 | -0.91 | -2.09 | -7.13 |
| Normalized Diluted EPS | -0.21 | -0.59 | -0.57 | -1.30 | -4.46 |
| Average Basic Shares Outstanding | 3.48M | 1.40M | 1.40M | 756.80K | 278.70K |
| Average Diluted Shares Outstanding | 3.48M | 1.40M | 1.40M | 756.80K | 278.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |